Switching from a 2-dose to a 1-dose program of gender-neutral routine vaccination against human papillomavirus in Canada: a mathematical modelling analysis
If the average duration of 1-dose protection is longer than 25 years, a 1-dose HPV vaccination program would protect those vaccinated during their peak ages of sexual activity and prevent a similar number of HPV-related cancers as a 2-dose program, while being a more efficient use of vaccine doses.
Authors
- Jean‐François Laprise (ORCID: https://orcid.org/0009-0009-7938-1400)
- Marc Brisson (ORCID: https://orcid.org/0000-0003-3912-6447)
- Sarah Wilson (ORCID: https://orcid.org/0000-0002-2875-0036)
- Mélanie Drolet
- Ashleigh R. Tuite (ORCID: https://orcid.org/0000-0002-4373-9337)
- Gina Ogilvie (ORCID: https://orcid.org/0000-0001-5783-4493)
- Chantal Sauvageau (ORCID: https://orcid.org/0000-0002-4300-1658)
- Éléonore Chamberland
- Gillian Lim (ORCID: https://orcid.org/0000-0002-5994-1038)
Institutions
- University of British Columbia (CA)
- Public Health Ontario (CA)
- Centre hospitalier de l'Université Laval (CA)
- Université Laval (CA)
Publication Details
- Journal
- Canadian Medical Association Journal
- Published
- 2024-10-06
- DOI
- https://doi.org/10.1503/cmaj.240787
- Citations
- 2
- Primary Topic
- Sex and Gender in Healthcare
- Type
- article
- Field-Weighted Citation Impact
- 1.09
Funders
- Bill and Melinda Gates Foundation
- Public Health Agency of Canada
- Public Health Agency
- Canadian Immunization Research Network
- Canadian Institutes of Health Research